Literature DB >> 21052999

Thirty-day morbidity and mortality of the laparoscopic ileal interposition associated with sleeve gastrectomy for the treatment of type 2 diabetic patients with BMI <35: an analysis of 454 consecutive patients.

Aureo L DePaula1, Alessandro Stival, Alfredo Halpern, Sergio Vencio.   

Abstract

BACKGROUND: The objective of this study was to evaluate the early results of the laparoscopic interposition of a segment of ileum associated with a sleeve gastrectomy (LII-SG) in order to treat patients with type 2 diabetes mellitus (T2DM) and BMI <35. Data regarding morbidly obese diabetic patients subjected to surgery has consistently been validated. To date, there is scarce information about morbidity and mortality related to the surgical treatment of a "true" typical diabetic population with BMI <35.
METHODS: The procedures were performed in 454 patients (322 male, 132 female). Mean age was 53.6 ± 8 years (range = 27-75). Mean BMI was 29.7 ± 3.6 kg/m(2) (range = 19-34.8). All patients had the diagnosis of T2DM for at least 3 years. Insulin therapy was used by 45.6% of patients. Mean duration of T2DM was 10.8 ± 5.9 years (range = 3-35). Mean hemoglobin A(1c) was 8.8 ± 1.9%. Dyslipidemia was observed in 78.4%, hypertension in 64.8%, nephropathy in 28.6%, retinopathy in 32.6%, neuropathy in 34.6%, and coronary heart disease in 13%.
RESULTS: There was no conversion to open surgery. All patients were evaluated postoperatively. Mortality was 0.4%. There were 29 major complications (6.4%) in 22 patients (4.8%) and 51 minor complications (11.2%). Reoperations were performed on 8 patients (1.7%). Twenty patients (4.4%) were readmitted to the hospital. Mean postoperative BMI was 25.8 ± 3.5 kg/m(2). Mean fasting plasma glucose decreased from 198 ± 69 to 128 ± 67 mg/dl and mean postprandial plasma glucose decreased from 262 ± 101 to 136 ± 43 mg/dl.
CONCLUSIONS: The laparoscopic ileal interposition associated with a sleeve gastrectomy was considered a safe operation with low rates of morbidity and mortality in a diabetic population with BMI < 35. An early control of postprandial glycemia was observed.

Entities:  

Mesh:

Year:  2011        PMID: 21052999     DOI: 10.1007/s00268-010-0799-3

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  28 in total

Review 1.  Diabetes in Asia: epidemiology, risk factors, and pathophysiology.

Authors:  Juliana C N Chan; Vasanti Malik; Weiping Jia; Takashi Kadowaki; Chittaranjan S Yajnik; Kun-Ho Yoon; Frank B Hu
Journal:  JAMA       Date:  2009-05-27       Impact factor: 56.272

2.  The Second International Consensus Summit for Sleeve Gastrectomy, March 19-21, 2009.

Authors:  Michel Gagner; Mervyn Deitel; Traci L Kalberer; Ann L Erickson; Ross D Crosby
Journal:  Surg Obes Relat Dis       Date:  2009-06-13       Impact factor: 4.734

3.  Bands and bypasses: 30-day morbidity and mortality of bariatric surgical procedures as assessed by prospective, multi-center, risk-adjusted ACS-NSQIP data.

Authors:  Robert T Lancaster; Matthew M Hutter
Journal:  Surg Endosc       Date:  2008-09-20       Impact factor: 4.584

4.  Reinforcing the staple line during laparoscopic sleeve gastrectomy: prospective randomized clinical study comparing three different techniques.

Authors:  Giovanni Dapri; Guy Bernard Cadière; Jacques Himpens
Journal:  Obes Surg       Date:  2009-12-11       Impact factor: 4.129

5.  Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients.

Authors:  Elza Muscelli; Andrea Mari; Arturo Casolaro; Stefania Camastra; Giuseppe Seghieri; Amalia Gastaldelli; Jens J Holst; Ele Ferrannini
Journal:  Diabetes       Date:  2007-12-27       Impact factor: 9.461

Review 6.  The physiology of glucagon-like peptide 1.

Authors:  Jens Juul Holst
Journal:  Physiol Rev       Date:  2007-10       Impact factor: 37.312

7.  Prospective randomized controlled trial comparing 2 versions of laparoscopic ileal interposition associated with sleeve gastrectomy for patients with type 2 diabetes with BMI 21-34 kg/m(2).

Authors:  Aureo L De Paula; Alessandro R Stival; Antonio Macedo; José Ribamar; Marcio Mancini; Alfredo Halpern; Sérgio Vencio
Journal:  Surg Obes Relat Dis       Date:  2009-11-10       Impact factor: 4.734

8.  Effects of intensive glucose lowering in type 2 diabetes.

Authors:  Hertzel C Gerstein; Michael E Miller; Robert P Byington; David C Goff; J Thomas Bigger; John B Buse; William C Cushman; Saul Genuth; Faramarz Ismail-Beigi; Richard H Grimm; Jeffrey L Probstfield; Denise G Simons-Morton; William T Friedewald
Journal:  N Engl J Med       Date:  2008-06-06       Impact factor: 91.245

9.  Hormonal evaluation following laparoscopic treatment of type 2 diabetes mellitus patients with BMI 20-34.

Authors:  Aureo Ludovico DePaula; A L V Macedo; V Schraibman; B R Mota; S Vencio
Journal:  Surg Endosc       Date:  2008-10-02       Impact factor: 4.584

10.  Type 2 diabetes mellitus: a high-risk condition for cardiovascular disease irrespective of the different degrees of obesity.

Authors:  S H Song; C A Hardisty
Journal:  QJM       Date:  2008-09-06
View more
  12 in total

1.  Laparoscopic sleeve gastrectomy with ileal interposition (SGIT): a modified duodenal switch for resolution of type 2 diabetes mellitus in lesser obese patients (BMI < 35).

Authors:  Michel Gagner
Journal:  World J Surg       Date:  2011-01       Impact factor: 3.352

Review 2.  Surgical approaches to the treatment of obesity.

Authors:  John B Dixon; Nora E Straznicky; Elisabeth A Lambert; Markus P Schlaich; Gavin W Lambert
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-07-05       Impact factor: 46.802

3.  Bariatric surgery in class I obesity : a Position Statement from the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO).

Authors:  Luca Busetto; John Dixon; Maurizio De Luca; Scott Shikora; Walter Pories; Luigi Angrisani
Journal:  Obes Surg       Date:  2014-04       Impact factor: 4.129

Review 4.  Efficacy and Safety of the Over-the-Scope Clip (OTSC) System in the Management of Leak and Fistula After Laparoscopic Sleeve Gastrectomy: a Systematic Review.

Authors:  Saeed Shoar; Lauren Poliakin; Zhamak Khorgami; Rebecca Rubenstein; Moamena El-Matbouly; Jun L Levin; Alan A Saber
Journal:  Obes Surg       Date:  2017-09       Impact factor: 4.129

5.  Surgical treatment of type 2 diabetes in patients with BMI below 35: mid-term outcomes of the laparoscopic ileal interposition associated with a sleeve gastrectomy in 202 consecutive cases.

Authors:  Aureo L DePaula; Alessandro R Stival; Carolina C L DePaula; Alfredo Halpern; Sergio Vencio
Journal:  J Gastrointest Surg       Date:  2012-02-18       Impact factor: 3.452

6.  Eating behavior and glucagon-like peptide-1-producing cells in interposed ileum and pancreatic islets in rats subjected to ileal interposition associated with sleeve gastrectomy.

Authors:  Helene Johannessen; Yosuke Kodama; Chun-Mei Zhao; Mirta M L Sousa; Geir Slupphaug; Bård Kulseng; Duan Chen
Journal:  Obes Surg       Date:  2013-01       Impact factor: 4.129

7.  Ileal interposition coupled with duodenal diverted sleeve gastrectomy versus standard medical treatment in type 2 diabetes mellitus obese patients: long-term results of a case-control study.

Authors:  Diego Foschi; Luca Sorrentino; Igor Tubazio; Consuelo Vecchio; Tarcisio Vago; Maurizio Bevilacqua; Andrea Rizzi; Fabio Corsi
Journal:  Surg Endosc       Date:  2018-09-17       Impact factor: 4.584

Review 8.  Efficacy of metabolic surgery on HbA1c decrease in type 2 diabetes mellitus patients with BMI <35 kg/m2--a review.

Authors:  Kee Yuan Ngiam; Wei-Jei Lee; Yi-Chih Lee; Anton Cheng
Journal:  Obes Surg       Date:  2014-01       Impact factor: 4.129

9.  Bariatric surgery for type 2 diabetes reversal: the risks.

Authors:  Andrei Keidar
Journal:  Diabetes Care       Date:  2011-05       Impact factor: 19.112

10.  Bariatric surgery: an IDF statement for obese Type 2 diabetes.

Authors:  J B Dixon; P Zimmet; K G Alberti; F Rubino
Journal:  Diabet Med       Date:  2011-06       Impact factor: 4.359

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.